These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 15520171)

  • 1. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
    Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
    Hempen PM; Zhang L; Bansal RK; Iacobuzio-Donahue CA; Murphy KM; Maitra A; Vogelstein B; Whitehead RH; Markowitz SD; Willson JK; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 2003 Mar; 63(5):994-9. PubMed ID: 12615714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and PEA-3 binding sites.
    Tardif G; Reboul P; Dupuis M; Geng C; Duval N; Pelletier JP; Martel-Pelletier J
    J Rheumatol; 2001 Jul; 28(7):1631-9. PubMed ID: 11469472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
    Rossi MR; Ionov Y; Bakin AV; Cowell JK
    Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
    Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
    Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
    Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
    Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
    Goumans MJ; Valdimarsdottir G; Itoh S; Rosendahl A; Sideras P; ten Dijke P
    EMBO J; 2002 Apr; 21(7):1743-53. PubMed ID: 11927558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan profile.
    Patsos G; André S; Roeckel N; Gromes R; Gebert J; Kopitz J; Gabius HJ
    Glycobiology; 2009 Jul; 19(7):726-34. PubMed ID: 19293232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
    Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
    Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
    Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
    Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
    Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
    Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
    Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.
    Ijichi H; Otsuka M; Tateishi K; Ikenoue T; Kawakami T; Kanai F; Arakawa Y; Seki N; Shimizu K; Miyazono K; Kawabe T; Omata M
    Oncogene; 2004 Feb; 23(5):1043-51. PubMed ID: 14762439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
    Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
    Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel dominant negative Smad2 mutation in a TGFbeta resistant human carcinoma cell line.
    Tsang KJ; Tsang D; Brown TN; Crowe DL
    Anticancer Res; 2002; 22(1A):13-9. PubMed ID: 12017275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.